title: Antithrombin III prevents blood pressure elevation and proteinuria induced by high salt intake in pregnant stroke-prone spontaneously hypertensive rats.
abstract: In pregnant stroke-prone spontaneously hypertensive rats, salt-loading causes symptoms similar to those of human preeclampsia, such as hypertension and proteinuria. To seek evidence of the therapeutic potential in preeclampsia of antithrombin III (AT III), which is a serine protease inhibitor active on various enzymes of the coagulation cascade, we examined the effect of consecutive treatment with AT III on hypertension and proteinuria in this animal model. Salt-loading (2% NaCl diet) caused a significant elevation of systolic blood pressure on day 15-17 and of urinary protein excretion on day 17-19 of gestation, as compared with animals fed a normal diet. AT III, administered i.v. at a dose of 60 or 300 U/kg/d for 10 d from day 9-11 to 18-20, attenuated these pathological changes in a dose-dependent manner. Histological examination of the kidney revealed that AT III prevented the occurrence of arteriosclerosis and thickening of the capillary basement membrane. However, the pathological changes induced by salt-loading were not attributable to activation of the blood coagulation system. These results demonstrate that AT III has preventive action against salt-induced hypertension and proteinuria in pregnancy through a mechanism largely independent of its anticoagulant action. AT III may thus be beneficial for the treatment of clinical symptoms of preeclampsia.
authors.affiliation: Pharmacology Laboratories, Green Cross Corporation, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Shinyama
authors.forename: K
authors.initials: K
authors.lastname: Yamanaga
authors.forename: T
authors.initials: T
authors.lastname: Akira
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: M
authors.initials: M
authors.lastname: Yaguchi
authors.forename: M
authors.initials: M
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Kagitani
mesh_terms: D000818:Animals; D000990:Antithrombin III / Q000494:pharmacology* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000473:pathology / Q000517:prevention & control*; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D011225:Pre-Eclampsia / Q000188:drug therapy; D011247:Pregnancy; D011507:Proteinuria / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D012965:Sodium Chloride / Q000008:administration & dosage
chemical_list: D012965:Sodium Chloride; D000990:Antithrombin III